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Large variation in assay performance and outcomes of CSF Aβ1-42, total Tau (Tau), and phosphorylated Tau (pTau) (at amino
acid 181) levels is observed between laboratories. The aim of this study was to assess the diﬀerences in assay procedures between
several experienced international laboratories, as potential sources of error. 14 groups performed the Aβ42, Tau, and pTau assays
according to the guidelines of the manufacturer. Diﬀerences in analytical procedures between the laboratories were monitored. At
least23itemsinassayprocedureswereidentiﬁedthatvariedbetweenthelaboratories,includingproceduresforwashing,pipetting,
incubation, ﬁnishing, and sample handing. In general, the inter- and intra-assay variation between the groups was generally below
10% for all three assays. We concluded that 17 international centers that use the same assays for Aβ42, Tau and pTau on a regular
basis do not uniformly adhere to the procedures recommended by the manufacturer. For harmonization of intercenter results of
these biomarkers standardization of protocols is highly needed.
1.Background
In the aging population the number of Alzheimer Disease
(AD) patients is expected to increase [1]. However, the diag-
nostic accuracy of the clinical criteria is relatively low (sen-
sitivity 80% and speciﬁcity of 70%) [2]). With this in mind,
biological markers in body ﬂuids are urgently needed to sus-
tain diagnosis, as they are an objective tool and reﬂect ongo-
ing processes. Biomarkers can aid not only in early diagnosis
orindiﬀerentialdiagnosisbutalsoinestimationofprognosis
and, ideally, monitoring progression of this disease.
The concentrations of Amyloid-beta(1-42) (Aβ42), total
Tau (Tau), and Tau phosphorylated at position 181 (pTau)
in cerebrospinal ﬂuid (CSF) of AD patients can be used
as biomarkers [3]. Several laboratories measure these three
biomarkers in CSF, and a major challenge is to translate the
technology from the lab to clinical practice. To reach this
goal, the technique should be robust and laboratories should
be adequately experienced [4]. In addition, results obtained
in diﬀerent centres should be comparable to the highest
p o s s i b l ed e g r e e[ 5]. The comparability of results between
diﬀerent centres is crucially dependent on the performance
of the biomarker tests in the various institutions, and this
can be assessed with an external quality assessment scheme.
No such scheme was available and that is why we took
the initiative in 2004 to send samples to a number of
laboratories with previous experience in performing these
CSF biomarker assays, with their own ELISA assays. The
results revealed large variation in the concentrations of the
three biomarkers between the diﬀerent laboratories and a
diﬀerence in variation at each evaluated time point [6].
Overall variation for Tau was slightly better in 2008 than in
2004, since the mean interlaboratory CV was 21% in 2004
and 16% in 2008. For pTau the mean between-laboratory2 International Journal of Alzheimer’s Disease
CV increased slightly, that is, from 13% in 2004 to 15% in
2008. The largest overall change was seen for Aβ42, where
the between-laboratory variation increased from 31% to
37%. The introduction of other ELISA methods appeared
to be responsible for this overall increase in variation.
Laboratories that used the Innotest assays improved the
between-laboratory variation of Aβ42 from 30% in 2004 to
22% in 2008, suggesting that experience and standardization
of assay procedure may contribute signiﬁcantly to reduce
between laboratory variation. With the aim to improve
between-laboratory performance we set out to identify the
speciﬁc diﬀerences in procedures between laboratories. For
this, we organised a hands-on workshop at the end of 2009.
2. Methods
26 participants from 17 diﬀerent international centres with
previous experience in performing the assays were divided
in 14 groups, and every group performed the Aβ42, Tau,
and pTau assays. The participants used their own pipettes.
Identical samples containing pooled anonymised CSF sam-
ples, with concentrations of these biomarkers covering
concentrations observed in controls, in AD patients and an
intermediate value, were provided to the groups. Standard
curves were diluted by each group according to the pro-
tocol, starting with dissolving the solid powder. All groups
analysed the same samples, and the assays were performed
simultaneously in the same laboratory and used the protocol
(incubation procedures) as provided by the manufacturer.
The standards and samples were analysed in duplicate. One
exception was the incubation temperature of the Tau assay,
whichshouldbeinanincubatorat25±2◦C,andwasatroom
temperature due to practical reasons. During the perfor-
manceoftheassays,thetwopersonsineverygroupdiscussed
their usual laboratory practice in performing the assays and
diﬀerenceswererecorded.Theintra-andinterassayvariation
in concentrations of the pooled CSF samples was calculated.
The analysis was done blindy for the concentrations.
3.DataAnalysis
The standard curves were calculated using a 5-parameter
logistic (5PL) curve ﬁtting on the Biorad Microplate Man-
ager Software. The mean and standard deviations of the
concentrations in the pools were calculated per group.
4. Results
4.1. Variation in Assay Procedures. Table 1 lists the items that
were noticed to vary among the laboratories participating in
the workshop. The items involved procedures for pipetting,
incubation, washing, ﬁnishing, and sample handling.
4.2. Inter-Assay Variation during the Workshop. Several items
listed in Table 1 were standardised during the workshop
due to its setup. Therefore, we were able to evaluate the
inter-assay variation under circumstances that excluded
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Figure 1: Concentrations of (a) Aβ42, (b) Tau, and (c) pTau in
CSF pools containing low, medium, and high concentrations of
these biomarkers per group. Aβ42, Tau, and pTau concentrations
in samples were analysed blinded for the concentrations. Triangle:
pool 3; Square: pool 2; Diamond: pool 1.
several items that varied between the laboratories (Table 2),
providing an indication of the relative contribution of these
sources of error. Figure 1 shows the concentrations of the
CSF pools for each group. The results of two groups strongly
deviated from the mean outcomes. The cause was identiﬁed
aslackofexperience(group3)andanerrorinthecalculation
of the dilution of the standard to make the standard curve
(group 11). For Tau, no outliers were identiﬁed while, for
pTau, the outcomes of the concentration of the highest pool
were deviating in group 14. The numbers in Table 1 provide
the concentrations and variation coeﬃcients.
The intra-assay variation based on the concentrations of
the unknowns was high for pool 1 and 2 of Abeta but on
average was below 10% for Tau and pTau.International Journal of Alzheimer’s Disease 3
Table 1: Procedures that varied between the laboratories.
Pipetting
Standardised due to
t h ed e s i g no ft h e
workshop
(1) Use of diﬀerent pipette tip for each
standard-sample-dilution tips compared to one tip
(2) Wiping oﬀ the tip with a tissue
(3) Some labs apply “inverse pipetting”
(4) Use of a multichannel pipet rather than a single-channel
pipet for pipetting the samples of Aβ42 from the dilution
plate and pipetting secondary antibodies
(5) The labs use diﬀerent brands of pipettes
Incubation
(6) Some labs incubate the Aβ42 and Tau ELISA at 25◦C,
others at room temperature
Yes: at room
temperature
(7) Several labs report problems with the air conditioning in
summer Yes
(8) Several labs shake the plate (at 300rpm) during the whole
incubation period while several other labs do this just for one
hour and then incubate the plate without further shaking,
other labs shake it several minutes, and some do not shake at
all during the incubation
Yes
(9) Several labs always incubate the samples in the dark
Washing
(10) Several labs use an automatic wash machine, others do it
by manually Yes
(11) Tau: several labs wash 5 times instead of 4 times Yes
(12) The concentrated wash buﬀer: several labs heat it up to
dissolve the crystals. others do not, they wait untill all crystals
are dissolved
(13) Diﬀerent labs use diﬀerent amounts of wash buﬀer (300
or 400μL) Yes
Finishing
(14) The TMB incubation: several labs perform it in dark,
others do not Yes
(15) Several labs stop the incubation with 50μLH 2SO4,
others use 100μL
(16) Several labs use diﬀerent brands of microplate readers
and diﬀerent reference values for the reader. Yes
(17) Diﬀerent curve ﬁtting procedures are followed (straight
line, 5 PL, etc.), Yes
Sample handing
(18) Several labs close the standard vial during the
procedures
(19) Between the diﬀerent assays (Aβ42, Tau, and P-Tau) the
samples are stored by several labs at 4◦C. Others use new
aliquots stored at −20◦C.
Others leave the samples at room temperature.
Yes
Other
(20) Several labs do not use the polypropylene plate for the
Aβ measurement, which is delivered by the assay
manufacturer.
Yes
(21) Several labs use gloves to perform the assays.
(22) Aβ42: Several labs do not use the 1500pg/mL standard. Yes
(23) Several labs use MilliQ water, others use distilled water. Yes4 International Journal of Alzheimer’s Disease
Table 2: Variation in outcomes of CSF concentrations of the three biomarkers between the 14 groups.
Aβ1-42 Total Tau P-Tau181P
Concen-
tration
(pg/mL)
Inter-assay
variation %
CV (all
groups)
%C V
(group 3
and 11
removed)
Intra-assay
variation
(stdev)
Concen-
tration
(pg/mL)
Inter-assay
variation %
CV
Intra-assay
variation
(stdev)
Concen-
tration
(pg/mL)
Inter-assay
variation %
CV
Intra-assay
variation
(stdev)
Pool 1 203 49.3 7.63 24.3 (23.6) 196 8.4 4.3 (2.0) 46 16.5 8.5 (7.1)
Pool 2 448 39.6 10.33 11.4 (19.3) 385 8.7 3.6 (3.6) 102 9.3 3.5 (5.0)
Pool 3 1002 17.0 9.99 4.6 (9.5) 902 7.4 2.9 (2.9) 181 6.2 3.0 (2.1)
5. Discussion
5.1. Procedural Diﬀerences. The principle aim of this study
was to address the issue of procedural diﬀerences as a source
of variation between outcomes of CSF biomarker analysis.
One of the results of workshop was a list with diﬀerences in
procedures among the labs, containing 23 items. Variation
was observed in all phases of the protocol. Some of the items
were prescribed in the protocol but were not adhered to.
Examples of these items are the use of polypropylene plate
forsamplepredilution,theinclusionof1500pg/mLstandard
in the curve, the use of 50μLH 2SO4in the Aβ42 assay, and
the use of 5PL curve ﬁtting and incubation temperature of
25 ±2◦C for total Tau.
Thetypeofpipetteisnotprescribedbythemanufacturer,
neither was the mode of pipetting. We do not expect wiping
oﬀ the tips, which was historically done with speciﬁc types
of tissues; inverse pipetting and the pipette brand are factors
inducing much variation, as long as one mode of pipetting
of the samples is consistently used during the assays. The
use of a single pipette versus using a multichannel pipette
may inﬂuence the time needed to ﬁll an entire plate and
can be important when incubation time is short, such as
for Aβ42. Use of a single tip can inﬂuence the standard
curve accuracy. For preparation of standards a new tip for
each concentration is required. During pipetting in the plate,
multiple tips are recommended. However, the magnitude of
this eﬀect, if any, should be tested, to provide a better basis
for recommendation.
Incubation temperatures, incubation in the dark, and
shaking were other items that varied between the labora-
tories. Room temperature can vary from 18◦Ci nw i n t e rt o
30
◦C in summer time. Whether this variation in incubation
conditions is relevant for the current tests is not known
but likely. This should be tested, and explicit information
regarding inﬂuence of shaking and temperature require-
ments should be provided in assay protocols.
Regarding exclusion of the 1500pg/mL standard in
the curve, this is considered highly relevant. We did a
recalculation of the pools for one of the groups on a
curve ﬁtting without 1500pg/mL standard and the outcomes
diﬀered by 7.6%, 9.4%, and 7.2% for pool 1, 2 and 3 from
the original data. This is therefore seen as an important
additional source of variation.
Washing procedures (number of washing steps, volume,
purityofwashingsolutions)areimportantissuesinﬂuencing
variation and background. This can lead to removing
antibody-antigen complexes from the plate when washing
too much, as well as insuﬃcient removal of unbound
complexes, thereby causing high background. Therefore,
our recommendation is to adhere to the protocols from
the manufacturers. Furthermore, incomplete dissolution of
crystals from the washing buﬀer may lead to aberrant buﬀer
concentration when only part of the buﬀer is used.
The diﬀerence in volume of the stop-solution H2SO4
probably does not inﬂuence the outcomes, as long as it is
performed for all samples in one test similarly, as the pH
of the reaction mixture is only marginally inﬂuenced by
variation in the volume of the stop solution.
Sample handling (storage at 4◦C or repeated freezing)
can be very important as well, speciﬁcally for instable
proteins. For the current proteins, Aβ42, Tau, and pTau,
a previous study has shown that repeated freezing and
storage at 4◦C do not have a signiﬁcant eﬀect on tau
concentrations while Aβ42 concentrations may be reduced
due to storage for a few days at 4◦C[ 7]. Results from
a n o t h e rs t u d y ,h o w e v e r ,r e p o r t e dn oe ﬀect of storage
temperatures on Aβ42 concentrations (Blennow, personal
communication). Closing the vial is important to avoid
losing the contents upon accidentally falling, and to avoid
contamination.
5.2. Inter- and Intra-Assay Variation in the Current Study.
For scientiﬁc purposes, ideally, the inﬂuence of each of the
procedures listed in Table 1 on the intra- and interassay
variation is systematically tested. The current study excluded
severalpotentialsourcesoferror,indicatedinthelastcolumn
of Table 1,s u c ha sd i ﬀerences in incubation temperatures,
washing, variation in standardised curve ﬁtting, and lot-to-
lot variation. The inter-assay variation in results obtained
during the workshop was below the limits for intra-assay
variation for all assays, with a few exceptions (Table 2),
suggesting that standardisation indeed leads to reduced
inter-assay variation. Variation for tau assays was on a
whole lower than that for Aβ42. This may be caused by
increased experience as Aβ42 assay was started with during
the workshop and the participants may have needed some
time to get used to the laboratory. Alternatively, the observed
variation may be the normal variation for these assays, as
these diﬀerences were similar to what has been reported
before in [6] and what we observe in our own laboratory.International Journal of Alzheimer’s Disease 5
Table 3: The eﬀect of using multiple assays of a single lot.
>6 lots 1 single lot
Aβ1-42 Concentration (pg/mL) 465 888 496 1003
% CV 13.9 12.1 7.6 8.4
n 37 37 17 17
Tau Concentration (pg/mL) 622 193 621 181
% CV 9.5 10.5 7.1 7.1
n 31 31 19 19
P-Tau181P Concentration (pg/mL) 123 38 135 41
% CV 7.7 10.7 5.7 9.9
n 30 30 18 18
n: number of determinations, which was performed within a total period of
four years for the left two columns (multiple lots), and within a period of
1.5 years for the single lots.
The importance of lot-to-lot variation is stressed by
the results in Table 3, showing the reduction of inter-assay
variation in our laboratory when we started using multiple
assays from the same batch, purchased at once.
Analytical variation for the current tests has so far been
published sparsely. The variation could be reduced if for
instance clear quality control criteria and WHO-approved
standards would be available. The issue of quality control
is currently addressed in a large multicenter study, and our
initiative has been adopted by the Alzheimers Association.
That study will among others lead to established reference
values.
The issue of preanalytical variation is not addressed
in the current study. Standardisation of CSF collection
and biobanking procedures would be another strategy to
tackle pre-analytical variation. We recently published such
guidelines for standardised CSF collection and biobanking
protocols, that was based on a broad consensus between
multiple centers [8]. Adherence to these guidelines will
reducevariationinducedbypre-analyticalfactorsaswelland
increase the quality of studies aimed at discovery and valid-
ation of novel biomarkers.
In conclusion, the evaluation of the workshop showed
that even under standardised conditions as in this workshop,
with the same protocol and laboratory circumstances, inter-
assay variation is comparable to intra-assay variation and is
acceptable for the large majority of groups. The inﬂuence of
several items that varied between the labs should be studied
and protocols should be adapted accordingly. Provision
of information on the inﬂuence of speciﬁc items in the
data sheets might be needed to convince the users of
this requirement. Lastly, it is required that protocols are
strictly followed. Reduction in variation is most critical for
CSF concentrations around the cutoﬀ points especially if
these guide decision making in individual patients. Eﬀorts
for standardisation and the establishment of international
reference laboratories and reference values will ultimately
increase the reliability of the assays. This will provide a basis
to include these biomarkers assays more prominently in the
diagnostic workup of Alzheimer’s disease.
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